Approach to follow-up of the patient with differentiated thyroid cancer and positive anti-thyroglobulin antibodies.
Anti-thyroglobulin antibodies are commonly identified in patients with differentiated follicular cell-derived thyroid cancer. When present, they interfere with the measurement of thyroglobulin (Tg), which is the primary biochemical marker used for disease surveillance, creating challenges in monitoring patients for residual or recurrent disease. Moreover, there is variability in measuring anti-Tg antibodies according to the different assays, such that not all patients with anti-Tg antibodies are identifiable on a single assay system. The persistence of anti-Tg antibodies, especially if levels are rising, may indicate persistent, recurrent, or progressive thyroid cancer. In contrast, declining anti-Tg antibody levels may indicate reduced tumor burden or the absence of disease. In this review, we will explore in a case-based manner the data supporting monitoring and treatment paradigms for patients with anti-Tg antibodies and will stress areas where more evidence is needed to better inform clinicians regarding the management of patients with this challenging situation.
Division of Endocrinology, Diabetes, and Metabolism, The Ohio State University College of Medicine, Arthur G. James Comprehensive Cancer Center, and Richard G. Solove Research Institute, Columbus, Ohio 43235, USA. matthew.ringel@osumc.edu
Matthew D
MD
Ringel
Fadi
F
Nabhan
D000328:Adult; D001323:Autoantibodies / Q000097:blood*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D013964:Thyroid Neoplasms / Q000276:immunology* / Q000628:therapy
D001323:Autoantibodies; C006606:anti-thyroglobulin